275 related articles for article (PubMed ID: 30278283)
21. Runx1/AML1 in normal and abnormal hematopoiesis.
Yamagata T; Maki K; Mitani K
Int J Hematol; 2005 Jul; 82(1):1-8. PubMed ID: 16105753
[TBL] [Abstract][Full Text] [Related]
22. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
23. Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.
Yamamoto K; Yakushijin K; Ichikawa H; Okamura A; Nagao S; Kakiuchi S; Kurata K; Kawamoto S; Matsui K; Nakamachi Y; Saegusa J; Matsuoka H; Minami H
Leuk Lymphoma; 2019 May; 60(5):1294-1298. PubMed ID: 30526151
[No Abstract] [Full Text] [Related]
24. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
Sitailo S; Sood R; Barton K; Nucifora G
Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
[TBL] [Abstract][Full Text] [Related]
25. A role for RUNX1 in hematopoiesis and myeloid leukemia.
Ichikawa M; Yoshimi A; Nakagawa M; Nishimoto N; Watanabe-Okochi N; Kurokawa M
Int J Hematol; 2013 Jun; 97(6):726-34. PubMed ID: 23613270
[TBL] [Abstract][Full Text] [Related]
26. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
27. [Phenotypic and genetic analysis of acute megakaryoblastic leukemia in young children with WT1, MLL-PTD and EVI1 genes].
Zhao L; Chen X; Li M; Deng H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jul; 38(7):690-693. PubMed ID: 34247380
[TBL] [Abstract][Full Text] [Related]
28. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
[TBL] [Abstract][Full Text] [Related]
29. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
[TBL] [Abstract][Full Text] [Related]
30. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
31. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.
Hyde RK; Kamikubo Y; Anderson S; Kirby M; Alemu L; Zhao L; Liu PP
Blood; 2010 Feb; 115(7):1433-43. PubMed ID: 20007544
[TBL] [Abstract][Full Text] [Related]
32. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
[TBL] [Abstract][Full Text] [Related]
33. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
34. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.
Ichikawa M; Asai T; Saito T; Seo S; Yamazaki I; Yamagata T; Mitani K; Chiba S; Ogawa S; Kurokawa M; Hirai H
Nat Med; 2004 Mar; 10(3):299-304. PubMed ID: 14966519
[TBL] [Abstract][Full Text] [Related]
35. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis.
Kalev-Zylinska ML; Horsfield JA; Flores MV; Postlethwait JH; Vitas MR; Baas AM; Crosier PS; Crosier KE
Development; 2002 Apr; 129(8):2015-30. PubMed ID: 11934867
[TBL] [Abstract][Full Text] [Related]
36. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
[TBL] [Abstract][Full Text] [Related]
37. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
38. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
39. Runx1 isoforms show differential expression patterns during hematopoietic development but have similar functional effects in adult hematopoietic stem cells.
Challen GA; Goodell MA
Exp Hematol; 2010 May; 38(5):403-16. PubMed ID: 20206228
[TBL] [Abstract][Full Text] [Related]
40. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
